RxDoctor Payments Data

John Donnelly, MD

Psychiatry · Oceanside, CANPI 1760566160

Payments from drug & device makers

$6,014in general payments, 2019–2025

Across 313 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Johnson & Johnson$666
  • Alkermes, Inc.$642
  • Teva Pharmaceuticals USA, Inc.$622
  • Otsuka America Pharmaceutical, Inc.$578
  • Sunovion Pharmaceuticals Inc.$562
  • plus $2K from 7 others

What the payments were for

  • Food & beverage$5,71995%
  • Education$2955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,014 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$17,392
Medicare patients
61
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate59$173,966
Invega TrinzaPaliperidone Palmitate20$166,857
IngrezzaValbenazine Tosylate15$108,715
Abilify MaintenaAripiprazole28$81,132
VraylarCariprazine Hcl41$58,961
AustedoDeutetrabenazine11$52,154
Lurasidone Hcl117$24,583
RexultiBrexpiprazole13$21,470
VivitrolNaltrexone Microspheres12$20,477
Aripiprazole144$15,913
Olanzapine221$11,944
Clozapine90$9,786
TrintellixVortioxetine Hydrobromide17$7,670
Quetiapine Fumarate303$6,597
Paliperidone ErPaliperidone23$5,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$666$340,82479 claims
Neurocrine Biosciences, Inc.Ingrezza$1,059$108,71515 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$578$102,60141 claims
AbbVieVraylar$461$58,96141 claims
Teva Pharmaceuticals USA, Inc.Austedo$622$52,15411 claims
Alkermes, Inc.Vivitrol$642$20,47712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →